Conventional cancer treatment modalities have several limitations including lack of sufficient
efficacy, serious untoward toxicity, as well as innate and acquired drug resistance. In …

Folate receptor α (FRα) came into focus as an anticancer target many decades after the
successful development of drugs targeting intracellular folate metabolism, such as …

Background In cancer therapy, molecularly targeted agents have the potential to maximize
antitumor efficacy while minimizing treatment-related toxicity. However, these agents may …

Folate receptors are up-regulated on a variety of human cancers, including cancers of the
breast, ovaries, endometrium, lungs, kidneys, colon, brain, and myeloid cells of …

Over the last 25+ years, the folate receptor (FR) has emerged as an attractive tumor
biomarker with the potential to be exploited for therapeutic purposes. Increasing evidence …

Introduction: Folate receptor− α (FR− α) has been established as a membrane marker for
ovarian cancer. In addition, it is frequently overexpressed in other major types of epithelial …

Targeted delivery via selective cellular markers can potentially increase the efficacy and
reduce the toxicity of therapeutic agents. The folate receptor (FR) has two glycosyl …

99mTc-EC20 is a folate receptor (FR)–targeted imaging agent consisting of the vitamin
folate conjugated to 99mTc. FR is expressed on a variety of epithelial cancers, with …

The membrane-bound folate receptor (FR) is overexpressed on a wide range of human
cancers, such as those originating in ovary, lung, breast, endometrium, kidney and brain …

For over a decade the folate receptor has been intensively investigated as a means for
tumor-specific delivery of a broad range of experimental therapies including several …